Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has commenced an offer to purchase for cash up to $600,000,000 aggregate principal amount of the Company’s outstanding …
Analyst David Risinger from Morgan Stanley presented five questions he would like to see answered in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) upcoming earnings report …
Analyst David Maris of Wells Fargo weighs in on Valeant Pharmaceuticals Intl Inc (NYSE:VRX) ahead of second-quarter earnings, stating that he doesn’t see any indication that the troubled drug maker …
Analyst Chris Schott of J.P.
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) announced that its Board of Directors has appointed Thomas W.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is up over 5% in pre-market trading after the company announced the appointment of new CEO Joseph Papa, …
After two consecutive winning days, the major indexes suffered losses on Thursday, with the iShares Nasdaq Biotechnology Index losing 1.14%.
Considerable strength remains visible among biotechnology stocks, as reflected by the 2.25 percent gain being posted by the iShares NASDAQ Biotechnology Index today.